Elanco Animal Health has been granted a patent for a method to improve reproductive and litter performance in animals. The method involves orally administering a therapeutic clay to the animal between day 3 of gestation and three weeks prior to farrowing. The clay has been shown to reduce embryonic loss, increase litter size, improve immune status, and enhance overall performance in the animals. GlobalData’s report on Elanco Animal Health gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Elanco Animal Health Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Elanco Animal Health, NSAID cancer drugs was a key innovation area identified from patents. Elanco Animal Health's grant share as of September 2023 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11738045B2) describes a method for improving the reproductive and litter performance of maternal animals, specifically pigs. The method involves orally administering a therapeutic clay to the animals between day 3 of gestation and three weeks prior to farrowing.

The clay can be formulated in a feed composition for easy oral administration to the animals. By following this method, several improvements in reproductive and litter performance can be achieved. These improvements include reducing embryonic loss, increasing litter size, increasing the number of live births, improving the immune status of the maternal animal, reducing the concentration of maternal fecal amino acids, reducing the concentration of maternal fecal short-chained amino acids, and increasing litter birth weight.

Furthermore, the method also focuses on specific immune markers in the maternal animals. It aims to increase the levels of IFN? and TNF-a, while decreasing the levels of TRAIL in the maternal animals. The levels of pre-farrowing TNF-a are found to be positively correlated with total wean, negatively correlated with subsequent stillborns, and positively correlated with subsequent mummies. On the other hand, the level of pre-farrowing TRAIL is negatively correlated with subsequent total born and subsequent born alive. The level of wean IFN-? is positively correlated with total wean.

In terms of litter performance, the method aims to increase the amount of young animal colostrum intake, reduce young animal pre-weaning mortality, reduce the number of young animals lost due to low viability, reduce the number of weaned young animals, improve the immune status of young animals at weaning, reduce the number of lightweight young animals from nursery to market, increase the number of young animals marketed per maternal animal, and increase calculated litter weight gain.

The patent also provides specific ranges for the amount of clay administered to the animals, depending on the stage of gestation and the type of feed composition used. For example, the amount of clay in a feed composition can range from about 0.1 lb/ton to 10 lb/ton, while the amount of clay administered to a sow can range from about 1.0 g/d to about 10 g/d.

Overall, this patented method offers a potential solution for improving the reproductive and litter performance of maternal animals, particularly pigs, by orally administering a therapeutic clay. The method focuses on various aspects of reproductive and litter performance, as well as specific immune markers, to achieve these improvements.

To know more about GlobalData’s detailed insights on Elanco Animal Health, buy the report here.

This content was updated on 25 January 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies